Herantis Pharma Plc
Press release 4 May 2020 at 9:00 am Eastern European Time
Herantis Pharma Plc ("Herantis") has published its newsletter for March-April 2020. The newsletter is also attached to this press release.
Herantis' newsletter is published every other month on the company's web site (https://herantis.com/news-events/#newsletter). It is also available by email subscription (https://herantis.com/subscribe/).
Further information:
Herantis Pharma plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company breaking the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates, CDNF and Lymfactin®, aim to revolutionize the treatment of Parkinson's disease and other neurodegenerative diseases, and of secondary lymphedema. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland with ticker symbol "HRTIS" and Nasdaq First North Growth Market Sweden with ticker symbol "HRNTS". Subscribe to Herantis' news at https://herantis.com/subscribe/.
Distribution:
Main media
www.herantis.com